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Background: Palliative care in Parkinson’s Disease (PD) patients considerably differs
from palliative care in oncology patients. Integrated care models are a concept to support
patients and improve management of PD symptoms. However, it is not known if the
access to PD patients at the end of life can be achieved through integrated care models.
Aim: To analyze an integrated model of care for PD patients with the aim to identify if
this integrated model of care has access to PD patients at the end of life.
Material and Methods: The Cologne Parkinson’s network was designed as a
randomized, controlled prospective clinical trial in order to increase quality of life of PD
patients. This innovative model of care integrated a neurologist in private practice, a
movement disorder specialist of the University Hospital and a PD nurse. Mortality rates
of PD patients during the study period of 6 months were registered and compared with
mortality rates of the general population of Germany according to the Federal Statistical
Office of Germany. The retrospective post-hoc analysis was conducted after completion
of the initial study at the University Hospital and neurologists’ practices in the greater area
of Cologne, Germany. Eligible patients had a diagnosis of idiopathic PD and were aged
25–85 years.
Results: Parkinson’s Disease patients in this trial had an even slightly lower mortality
rate as the general population (1.66 v. 2.1%). These results are contradictory and
speak for a substantial proportion of late-stage disease patients, who have not been
adequately included in this study or have been better treated within this trial. The
mean disease duration of patients in this study was around 6 years which resembles
the lower range of the mean disease duration at death of PD patients in general.
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Conclusions: The results of our post-hoc analysis show, that accessing PD patients in
the last phase of their disease is extremely difficult and nearly fails in spite of an integrated
care approach. Reasons for poor access and loss of follow-up at the end of life have to
be identified and care models for PD patients until the end of life should be developed
urgently.
Keywords: Parkinson, palliative care, end-of-life, integrated care, late-stage, network
INTRODUCTION
Despite a significant progress in treatment strategies and modern
therapy concepts neurodegenerative diseases like idiopathic
Parkinson’s disease (PD) or atypical Parkinsonian disorders
inevitably lead to progressive motor, neuropsychiatric and non-
motor symptoms (1–5). Dementias develops in up to 80% of
patients after 20 years (6), depressions in more than 40% of
patients and psychotic experiences are frequent in PD patients
(7). Reduced mobility implicates higher mortality as in the age-
related population, specifically due to infections (pneumonia,
urinary tract infections) or falls with consecutive fractures (8).
According to a recent meta-analysis, mortality in PD patients is
increased in a range of 0.9–3.8. The mean duration until death
ranges between 6.9 and 14.3 years, where increasing age and
development of dementia were most commonly associated with
increased mortality (9).
Palliative care in PD patients considerably differs from
palliative care provision in oncology patients, in terms of the
models of care, the provision and the duration. The beginning
of the palliative phase in PD is still not well defined but according
to a recent publication it lasts about 2.2 years for PD patients and
1.5 years for APS before death (10). Currently only occasionally
palliative care structures are integrated selectively during the
course of the disease. Patients with PD/APS die from infections as
a consequence of swallowing difficulties or injuries and fractures
as the consequences of falls (11), but hardly ever in hospices and
more seldom at home than patients of other oncological diseases
(12).
In the last years in the greater area of Cologne, Germany,
the Cologne Parkinson’s network was designed as a randomized,
controlled prospective clinical trial in order to increase quality
of life of PD patients. This innovative model of care integrated
a neurologist in private practice, a movement disorder specialist
and a PD nurse of the University Hospital. In consultation
hours at the practices of the neurologists’ patients met with
the integrated care team and individual neurological treatment
plans were designed. The PD nurse visited patients at home
regularly every 3 months and could be contacted in between
to follow and address patients’ Parkinson-related problems.
This integrated, multiprofessional, individual and personalized
therapy meeting individual needs of patients improved their
quality of life, motor functioning as well as non-motor
symptoms (13).
This integrated care model included PD patients, who were
able to visit a practice of a neurologist. Our retrospective post-hoc
analysis of the trial’s data aimed to detect whether this care model
managed to access or follow, respectively, also PD patients at the
end of life.
MATERIALS AND METHODS
This study was set up as a randomized controlled prospective
clinical study with two arms in the greater area of Cologne in
Germany.
The Cologne Parkinson Network (CPN) was established
together with movement disorders experts and a PD nurse from
the University Hospital of Cologne, Department of Neurology
(CE) together with 25 community neurologists.
The trial was conducted between February 2012 (first patient
first visit) and July 2015 (last patient last visit) and was approved
by the local ethics committee of the medical faculty of the
University of Cologne (No. 11-233). For further details of this
trial we refer to the published study (13). The study was registered
in the German Register for Clinical studies (DRKS00003452).
Briefly, patients were screened for potential involvement [age
25–85 years, exclusion criteria were unstable medical condition
as a co-morbidity, major depression (BDI-2 >30 points),
severe cognitive decline (PANDA <14 points)] by community
neurologists and presented in quarterly Parkinson’s consultation
hours together with the movement disorders expert and the PD
nurse. The time of the consultation was set as needed (up to
a maximum of 45min). Patients were randomized to either a
control group (CG) or an intervention group (IG). In the CG,
patients were included in the study at the baseline visit in the
Parkinson’s consultation hour and continued regular German
neurological treatment. This included visits at the community
neurologists practice about every 3 months (baseline, 3 months,
6 months). Once included, the PD nurse obtained questionnaires
and surveyed clinical parameters (e.g., UPDRS III ) at baseline
and every 3months. Patients had access to regular physiotherapy,
occupational or speech therapy. Access to different medications
was the same for both treatment arms.
The IG-treatment additionally included the development
of an individual treatment plan, regular home visits of a
PD nurse (every 3 months or whenever necessary on short
notice) and a telephone hotline. Individual treatment plans were
reviewed every 4 weeks and adapted according to individual
patients’ needs. Furthermore, the PD nurse synchronized the
therapeutic pharmacological intervention with the program of
speech therapists or physiotherapists. Thus, whenever necessary,
rapid therapeutic modifications could be achieved.
Primary outcome parameter was the PDQ-39 to assess
quality of life of patients. Changes in mood, motor and
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non-motor functioning and cognition (BDI-2, UPDRS
III, NMS-Score, PANDA) were evaluated as secondary
outcome parameters. Daily medication was converted to the
Levodopa equivalence dose according to published conversion
rates (14).
Mortality rates of patients during the study period of 6months
were registered and compared with mortality rates of the general
population of Germany according to the Federal Statistical Office
of Germany (www.destatis.de).
RESULTS
A total of 1,400 patients were screened for eligibility. 300 patients
were eligible, included and randomized. Patients were equally
randomly assigned to an intervention (IG) and control group
(CG). Mean age at baseline was 69.8 ± 8.4 for the IG and 69.9
± 7.8 years in the CG. 132 patients in the IG and 125 in the CG
completed the study, 37 patients dropped out (see Figure 1 for
reasons). Overall, 5 patients deceased during the study period in
the IG, which is 1.66% of the total study population (n = 300).
Reasons for death were heart failure due to myocardial infarction
(n = 3), hospitalization after femoral neck fracture, secondary
aspiration pneumonia and sepsis (n = 1) and in consequence
of pancreatic cancer (n = 1). None of the patients in the CG
deceased.
PDQ-39 improved more in IG compared to CG (2.2 points
(95%CI−4.4 to 0.1); p= 0.044). Likewise, change scores between
IG and CG favored IG for UPDRS III (p < 0.001, mean change
3.3, 95% CI−4.9 to−1.7) and PD-NMS (p< 0.001, mean change
11.3, 95% CI−17.1 to−5.5).
The primary outcome parameter significantly improved in the
IG compared to the CG over a 6-month period (2.2 points (95%
CI −4.4 to 0.1); p = 0.044). The secondary outcome UPDRS
improved in the IG after 6 months (p < 0.001, mean change
3.3, 95% CI −4.9 to −1.7). The scores of the PD-NMS improved
likewise after 6 months in favor of the IG (p < 0.001, mean
change 11.3, 95% CI −17.1 to −5.5). No changes were detected
for the cognition (PANDA) or depressive symptoms (BDI-2). For
an overview of baseline characteristics see Table 1.
According to the mortality tables of the general population
the mean mortality rate for the years 2012–2014 is 2.1%
(mean of yearly mortality rates for women/men) for citizen
aged 60–80 years (as comparable to the set of the study
patients: mean age of patients ± standard deviation)
https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/
Bevoelkerung/Sterbefaelle/Sterbefaelle.html;jsessionid=
CC24B4774EDE040EE924FA2B881F0EE9.cae4%22%20/l
%20%22Tabellen%22). As such, the group of PD patients in this
trial had an even lower mortality rate as the general population
(1.66 v. 2.1%).
FIGURE 1 | Trial profile.
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TABLE 1 | Baseline characteristics IG and CG.
Outcome parameter Intervention group (IG)
Mean and SD
IG
n =
Control group (CG)
Mean and SD
CG
n =
p-value*
Age in years 69.8 ± 8.4 131 69.9 ± 7.8 132 0.924
Women/men 47/85 52/80 0.518
Disease duration/time since diagnosis in years 6.2 ± 6.2 126 5.5 ± 5.2 124 0.716
Hoehn and Yahr stage 2.5 ± 0.8 132 2.6 ± 0.8 125 0.687
Primary Outcome: PDQ-39 Total Score 26.0 ± 14.8 132 27.7 ± 15.6 125 0.407
Subscale mobility 32.1 ± 26.6 132 31.9 ± 24.3 125 0.882
Subscale activities of daily living 27.9 ± 23.6 132 28.9 ± 23.2 125 0.661
Subscale emotional well-being 27.3 ± 20.9 132 31.9 ± 19.6 125 0.072
Subscale stigma 17.4 ± 16.1 132 19.6 ± 20.2 125 0.815
Subscale social support 14.2 ± 19.6 132 14.5 ± 18.7 125 0.561
Subscale cognition 30.9 ± 19.6 132 33.3 ± 21.1 125 0.436
Subscale communication 22.0 ± 18.8 132 2.9 ± 21.1 125 0.927
Subscale bodily discomfort 36.0 ± 23.0 132 39.2 ± 23.4 125 0.266
SECONDARY OUTCOMES
UPDRS III 28.3 ± 9.1 132 28.0 ± 8.7 125 0.938
PANDA 24.7 ± 3.8 131 24.7 ± 3.5 125 0.795
BDI-2 12.0 ± 8.2 132 12.6 ± 7.3 125 0.266
NMS 53.9 ± 29.6 132 62.3 ± 34.6 125 0.057
Daily LEDD 612.9 ± 431.3 132 612.4 ± 390.6 125 0.659
OTHER
Medication use in %
Levodopa 34% 132 34% 125 0.921
Dopamine agonist 30% 132 31% 125 0.885
COMT inhibitor 9% 132 9% 125 0.927
MAO B blocker 16% 132 15% 125 0.862
Amantadin 11% 132 11% 125 0.911
Anticholinergic 0% 132 0.71% 125 0.101
Deep brain stimulation 4% 132 2.8% 125 0.422
*The p-values are from Pearson’s chi-square test (nominal data) or Kruskal-Wallis test (at least ordinal data), respectively.
DISCUSSION
This integrated care model was implemented including various
modalities to sustain quality of life in PD patients. The primary
and secondary outcome parameters were adequately achieved in
this study. Furthermore, this approach may have the opportunity
to improve access to PD patients also at the end of life. However,
the results of our post-hoc analysis show, that accessing PD
patients in the last phase of their disease is extremely difficult
and nearly fails in spite of an integrated care approach. Reasons
for loss of follow-up have to be identified and care models for
PD patients until the end of life should be developed urgently.
In this study, one major reason for poor access to and loss of
follow-up was the missing access to immobile patients. Patients
had to get access to neurologists’ practices. If they could not
turn up at the consultations as they were bed-bound at home
or in a nursing home, they could not be included and/or further
followed in the study. We are aware, that exclusion criteria like
dementia or severe depression are a serious limitation for the
inclusion of late stage PD patients. However, this ambitious trial
addressed successfully with a highly elaborated integrated care
program the various needs of PD patients. We are convinced
that not the exclusion criteria were the most limiting factor but
immobilization of late stage PD patients played a much more
important role.
This cohort showed an even lower mortality than the general
German population. Patients in the CG had an even lower
mortality rate compared to the IG, albeit a lacking individualized
therapy. These results are somewhat contradictory and speak
for a substantial proportion of patients, who were not been
adequately included in this study as we know that mortality
normally increases in PD. Another option for the low mortality
rates is an overall improved treatment within this study which
lead to a better monitoring process in both treatment arms.
Patients in both groups were closely monitored in terms of
motor functioning, detection of cognitive decline, depression or
further non-motor symptoms. It has been shown that a closer
monitoring in clinical trials improves patients outcomes (15).
The mean disease duration of patients in this study was around
6 years which resembles the lower range of the mean disease
duration at death of PD patients (9). This argues for an overall
representative group of PD patients in the late stage of the disease,
albeit motor symptoms, daily dosage of levodopa or Hoehn and
Yahr stage are moderately expressed.
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The time of integrating palliative care is critical, especially
as in PD/APS many obstacles and preconceptions have to
be overcome. The concept of early integration as described
by Shin and Temel for oncology patients (16) targets to
routinely assess for pain and other symptoms and regularly
inquire about a patient’s understanding of his disease and his
goals of care. This can provide an extra layer of support for
patients and their families by helping with more challenging
symptom management, psychosocial support, complex decision-
making, advance care planning, and transitions in care (16).
This concept can easily be adapted to PD patients in order to
integrate specialist palliative care at a disease stage at which
patients themselves can still decide on their affairs e.g., with
respect to advanced care planning like tube feeding, emergency
management, future care in a nursing home vs. staying at home
etc.
Specialist palliative care is typically accessible for patients
with cancer, albeit a variety of measures to improve access to
palliative care for people suffering from incurable non-cancer
conditions have been implemented more recently. At least shown
for Western Australia, in the last 10 years the proportion of
patients with non-cancer conditions getting access to specialist
palliative care was increasing about 6%. For PD patients this
increase was even bigger with 7.5% (17).
There have been some uncertainties, how patients with non-
cancer progressive neurological long-term conditions get access
to specialist palliative care. Van Vliet et al. reviewed this issue
for the UK and found heterogeneity in service provision and
integration between neurology and specialist palliative care
services, which varied not only between sites but also between
diseases (18). Especially PD patients, less APS, did not frequently
benefit from specialist palliative care. This asks for integrated care
models, e.g. specialist palliative care could be used as an “add-on”
approach to the existing integrated care model of the Parkinson’s
network if needed. Palliative care would then be provided in
addition to neurology care, without taking over.
Overall, not only in the late phase, PD patients show an
increased utilization of emergency departments. Gerlach et al.
reported that 16–45% of PD patients visit the emergency
department at least once per year. Additionally, patients were 1.5
fold more likely to be hospitalized and stayed 2–14 days longer
than controls (19). Beside the higher rates of hospitalization,
symptom burden increases with progressing disease. This leads to
a changing role of spouses toward a full-time caregiver. Spouses
and family members who form together with the patients the
“unit of care,” frequently report to feel isolated and discouraged,
without guidance and coordination from healthcare providers
and lacking information (20, 21). Finally, they are overstrained
after years of supporting and caring for/about the patients. Due
to this, a substantial proportion of PD patients dies in hospitals
rather than at home or in hospices (12)–even if this is not the
preferred place to die for PD patients (22). However, this depends
from the symptom burden of patients.
All these findings support the urgent need for advanced care
planning (ACP), one important aspect of palliative care. Most of
PD patients have not expressed their decisions for proceedings
at the end of life. This can include insertion of percutaneous
endoscopic gastrostomy (PEG) tube for nutrition as well as the
preferred place of death. Overall, reduced (or non-existent) APC
in PD patients may lead to an underrepresentation of PD patients
in a model of care as presented here. However, APC was not
surveyed in this study.
These findings ask for an intensive debate about ACP in PD,
as currently it seems not to be adequately addressed during the
course of PD. According to Walker, an ACP discussion might
“include the individual’s concerns, their important values or
personal goals for care, their understanding about their illness
and prognosis and their preferences for types of care or treatment
that may be beneficial in the future and the availability of these”
(23). Especially as written ACP are associated with less use of life
sustaining treatment, greater use of hospice and less likelihood
of hospitalization during end of life phase (24). Furthermore, it
was shown, that at least half of PD patients wish to discuss APC
early in the course of the disease (25). These findings encourage
the implementation of thorough ACP within integrated care
structures already at early disease stages.
All these different aspects ask for a further development of the
integrated care model, which includes the following principles:
a. Integration of specialist palliative care knowledge at a very
early point in the course of the disease with respect on the
acceptance of the diagnosis (e.g., once a year from the time
of the diagnosis),
b. Implementation of a clinical liaison/case manager (e.g., a PD
nurse) as a patient advocate, who takes care of the patient
during the course of the disease, especially in critical phases
of the disease (e.g., high symptom burden, late stage, etc.)
c. Integration of nursing homes, as PD patients in nursing homes
are underrepresented in neurological care
d. Integration of general practitioners/family doctors, as they
have a closer contact to patients’ families and know about
changing situations of care,
e. Dovetailing of neurological and specialist palliative care units
and outpatient services in order to use knowledge and the best
principles of both disciplines.
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